Ascend Laboratories recalls atorvastatin calcium tablets USP in 10, 20, 40 and 80 mg over failed dissolution tests
The tablets failed dissolution specifications, and the notice covers 141,984 bottles of atorvastatin calcium tablets USP sold across the U.S.
What to do
The notice does not give instructions. Read the official notice for details.
Note from Recalled Today: Don't stop taking a prescribed medicine before you talk to your pharmacist or doctor.
Recall details
- Product
- Atorvastatin Calcium Tablets USP, 80 mg, Rx Only, a). 90-count(NDC 67877-514-90), b). 500-count(NDC 67877-514-05), Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054; Atorvastatin Calcium Tablets USP, 20 mg, Rx Only, a). 90-count(NDC 67877-512-90), b). 500-count (NDC 67877-512-05), c). 1000-count(NDC 67877-512-10),Manufactured by…
- Company
- Ascend Laboratories, LLC
- Hazard
- Failed Dissolution Specifications
- Units
- 141,984 bottles
- Where sold
- U.S. Nationwide
- FDA classification
- Class II · Ongoing
- Classified by FDA
- October 10, 2025
- Recall started
- September 19, 2025
- FDA enforcement report
- October 22, 2025
- Identifiers
- Codes: Lot#: 25140249, Exp. Dec. 2026 Lot#: 25140247, Exp. Dec. 2026 Lot#: 24144999, Exp. Nov. 2026 Lot#: 24144942, Exp. Nov. 2026 Lot#: 24144845, Exp. Nov. 2026 Lot#: 24144713, Exp. Nov. 2026 Lot#: 24144652, Exp. Oct. 2026 Lot#: 24143898, Exp. Aug. 2026 Lot#: 24143412, Exp. Aug. 2026 Lot#: 24143582, Exp. Aug. 2026
- FDA recall number: D-0020-2026
- Codes: Lot #: 25140150, Exp. Dec. 2026 Lot #: 25140173, Exp. Dec. 2026 Lot #: 25140172, Exp. Dec. 2026 Lot #: 24144720, Exp. Nov. 2026 Lot #: 24144798, Exp. Nov. 2026 Lot #: 24144692, Exp. Oct. 2026 Lot #: 24143755, Exp. Aug. 2026 Lot #: 24143913, Exp. Aug. 2026 Lot #: 24143754, Exp. Aug. 2026 Lot #: 24143047, Exp. June 2026 Lot #: 24142936, Exp. July 2026
- FDA recall number: D-0019-2026
- Codes: Lot#: 25141249, Exp. Feb. 2027 Lot#: 24144938, Exp. Nov. 2026 Lot#: 24144868, Exp. Nov. 2026 Lot#: 24144867, Exp. Nov. 2026 Lot#: 24144458, Exp. Sep. 2026 Lot#: 24143994, Exp. Sep. 2026 Lot#: 24142987, Exp. July 2026 Lot#: 24143316, Exp. July 2026
- FDA recall number: D-0017-2026
- Codes: Lot#: 25140933, Exp. Feb. 2027 Lot#: 25140477, Exp. Dec. 2026 Lot#: 24144254, Exp. Oct. 2026 Lot#: 24144163, Exp. Sep. 2026 Lot#: 24143995, Exp. Sep. 2026
- FDA recall number: D-0018-2026
The headline, summary and steps above are written in plain English from the official notice below. Identifiers are copied exactly as the agency published them. Always check the official notice before you act.
Official notice
The notice's own wording from FDA.
- Product
- Atorvastatin Calcium Tablets USP, 80 mg, Rx Only, a). 90-count(NDC 67877-514-90), b). 500-count(NDC 67877-514-05), Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054 | Atorvastatin Calcium Tablets USP, 20 mg, Rx Only, a). 90-count(NDC 67877-512-90), b). 500-count (NDC 67877-512-05), c). 1000-count(NDC 67877-512-10),Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054. | Atorvastatin Calcium Tablets USP, 10 mg, Rx Only a) 90-count bottle (NDC 67877-511-90), b). 500-count bottle (NDC 67877-511-05), c). 1000-count bottle (NDC 67877-511-10) Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054. | Atorvastatin Calcium Tablets USP, 40 mg, Rx Only, a). 90-count (NDC 67877-513-90), b). 500-count (NDC 67877-513-05), c). 1000-count (NDC 67877-513-10), Manufactured by: Alkem Laboratories, Ltd. India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054.
- Reason for recall
- Failed Dissolution Specifications
- Classification
- Class II (Ongoing)
- Distribution
- U.S. Nationwide
- Quantity
- 141,984 bottles
Related recalls
Ascend Laboratories recalls amlodipine and olmesartan medoxomil tablets because they failed a dissolution test
The 10mg/40mg tablets, sold in 30-tablet bottles, were found to be out of specification due to dissolution, and 11,424 bottles were distributed nationwide within the United States.
Ascend Laboratories, LLC · 11,424 bottles.
Ascend Laboratories recalls Metoprolol Succinate Extended-Release Tablets, 25 mg, over failed dissolution specifications
The tablets failed dissolution specifications, and the notice covers 17,304 100-count bottles sold across the U.S.
Ascend Laboratories, LLC · 17,304 100-count bottles
Ascend Laboratories recalls amlodipine and olmesartan tablets over low olmesartan content
The 10 mg/20 mg tablets failed dissolution specifications and contain less olmesartan medoxomil than they should, and 6,192 bottles were sold nationwide in the USA.
Ascend Laboratories, LLC · 6,192 bottles